These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 20735287)

  • 1. Clinical review: topical ophthalmic use of cyclosporin A.
    Utine CA; Stern M; Akpek EK
    Ocul Immunol Inflamm; 2010 Oct; 18(5):352-61. PubMed ID: 20735287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical ophthalmic cyclosporine: pharmacology and clinical uses.
    Donnenfeld E; Pflugfelder SC
    Surv Ophthalmol; 2009; 54(3):321-38. PubMed ID: 19422961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Topical cyclosporine in ophthalmology: Pharmacology and clinical indications].
    Levy O; Labbé A; Borderie V; Laroche L; Bouheraoua N
    J Fr Ophtalmol; 2016 Mar; 39(3):292-307. PubMed ID: 26997607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of topical cyclosporin A in ocular graft-versus-host-disease.
    Kiang E; Tesavibul N; Yee R; Kellaway J; Przepiorka D
    Bone Marrow Transplant; 1998 Jul; 22(2):147-51. PubMed ID: 9707022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
    Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
    Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.
    Willen CM; McGwin G; Liu B; Owsley C; Rosenstiel C
    Eye Contact Lens; 2008 Jan; 34(1):43-5. PubMed ID: 18180683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [0.05% cyclosporine a for treatment of chronic severe ocular surface disease].
    Nochez Y; Denoyer A; Pisella PJ
    Can J Ophthalmol; 2009 Aug; 44(4):406-11. PubMed ID: 19606161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
    Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%.
    Malta JB; Soong HK; Shtein RM; Musch DC; Rhoades W; Sugar A; Mian SI
    Cornea; 2010 Dec; 29(12):1392-6. PubMed ID: 20847658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD; Pflugfelder SC; Tauber J; Foulks GN
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
    Toker E; Asfuroğlu E
    Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients.
    Hom MM
    Eye Contact Lens; 2006 Mar; 32(2):109-11. PubMed ID: 16538135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression.
    Gürdal C; Genç I; Saraç O; Gönül I; Takmaz T; Can I
    Curr Eye Res; 2010 Sep; 35(9):771-7. PubMed ID: 20795858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ophthalmic cyclosporine use in ocular GVHD.
    Lelli GJ; Musch DC; Gupta A; Farjo QA; Nairus TM; Mian SI
    Cornea; 2006 Jul; 25(6):635-8. PubMed ID: 17077652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
    Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
    Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease.
    Rao SN; Rao RD
    Cornea; 2006 Jul; 25(6):674-8. PubMed ID: 17077659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical cyclosporine-A in dry eye associated with chronic graft versus host disease.
    Kurt RA; Yalçindag N; Atilla H; Arat M
    Ann Ophthalmol (Skokie); 2009; 41(3-4):166-9. PubMed ID: 20214049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cyclosporine eye drops: A 4-year retrospective study (2009-2013)].
    Kauss Hornecker M; Charles Weber S; Brandely Piat ML; Darrodes M; Jomaa K; Chast F
    J Fr Ophtalmol; 2015 Oct; 38(8):700-8. PubMed ID: 26371985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
    Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
    Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of cyclosporine 0.05% in various ocular surface disorders].
    Maĭchuk DIu; Vasil'eva OA; Shokirova MM
    Vestn Oftalmol; 2014; 130(2):68-71. PubMed ID: 24864503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.